Medicinal Research Reviews,
Journal Year:
2022,
Volume and Issue:
42(6), P. 2067 - 2101
Published: June 21, 2022
Abstract
Ischemia/reperfusion
(IR)
injury
contributes
to
disability
and
mortality
worldwide.
Due
the
complicated
mechanisms
lack
of
proper
therapeutic
targets,
few
interventions
are
available
that
specifically
target
pathogenesis
IR
injury.
Regulated
cell
death
(RCD)
endothelial
parenchymal
cells
is
recognized
as
promising
intervening
target.
Recent
advances
in
suggest
small
molecules
exhibit
beneficial
effects
on
various
RCD
against
injury,
including
apoptosis,
necroptosis,
autophagy,
ferroptosis,
pyroptosis,
parthanatos.
Here,
we
describe
behind
these
novel
targets
explain
machinery
powering
molecules.
These
exert
protection
by
targeting
or
alleviate
Therapies
ideal
combination
multiple
types
have
shown
potent
synergetic
effects,
laying
foundation
for
strategies
attenuate
Pharmacological Reviews,
Journal Year:
2019,
Volume and Issue:
72(1), P. 320 - 342
Published: Dec. 23, 2019
Human
induced
pluripotent
stem
cells
(iPSCs)
have
emerged
as
an
effective
platform
for
regenerative
therapy,
disease
modeling,
and
drug
discovery.
iPSCs
allow
the
production
of
limitless
supply
patient-specific
somatic
that
enable
advancement
in
cardiovascular
precision
medicine.
Over
past
decade,
researchers
developed
protocols
to
differentiate
multiple
lineages,
well
enhance
maturity
functionality
these
cells.
Despite
significant
advances,
therapy
discovery
lagged
behind
other
fields
such
oncology.
We
speculate
this
paucity
is
due
a
previous
lack
efficient,
reproducible,
translational
model
systems.
Notably,
existing
testing
platforms
rely
on
animal
studies
clinical
trials,
but
investigations
models
inherent
limitations
interspecies
differences.
Moreover,
trials
are
inherently
flawed
by
assuming
all
individuals
with
will
respond
identically
ignoring
genetic
epigenomic
variations
define
our
individuality.
With
ever-improving
differentiation
phenotyping
methods,
iPSC-derived
unprecedented
opportunities
discover
new
targets
screen
compounds
disease.
Imbued
information
individual,
vastly
improve
ability
test
drugs
efficiently,
tailor
titrate
each
patient.
Journal of Extracellular Vesicles,
Journal Year:
2021,
Volume and Issue:
10(7)
Published: May 1, 2021
Apoptosis
is
a
naturally
occurring
process
generating
plenty
of
apoptotic
vesicles
(apoVs),
but
the
feature,
fate
and
function
apoVs
remain
largely
unknown.
Notably,
as
an
appealing
source
for
cell
therapy,
mesenchymal
stem
cells
(MSCs)
undergo
necessary
apoptosis
release
during
therapeutic
application.
In
this
study,
we
characterized
used
MSC-derived
to
treat
type
2
diabetes
(T2D)
mice,
found
that
were
efferocytosed
by
macrophages
functionally
modulated
liver
macrophage
homeostasis
counteract
T2D.
We
showed
can
induce
reprogramming
at
transcription
level
in
efferocytosis-dependent
manner,
leading
inhibition
accumulation
transformation
towards
anti-inflammation
phenotype
T2D
liver.
At
molecular
level,
discovered
calreticulin
(CRT)
was
exposed
on
surface
act
critical
'eat-me'
signal
mediating
apoV
efferocytosis
regulatory
effects.
Importantly,
demonstrated
CRT-mediated
contributes
therapy
with
alleviation
phenotypes
including
glucose
intolerance
insulin
resistance.
These
findings
uncover
functional
restores
ameliorates
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(3), P. 1912 - 1912
Published: Feb. 9, 2022
Anthracyclines,
such
as
doxorubicin,
are
effective
chemotherapeutic
agents
for
the
treatment
of
cancer,
but
their
clinical
use
is
associated
with
severe
and
potentially
life-threatening
cardiotoxicity.
Despite
decades
research,
options
remain
limited.
The
mitochondria
commonly
considered
to
be
main
target
doxorubicin
mitochondrial
dysfunction
hallmark
doxorubicin-induced
Here,
we
review
pathogenic
mechanisms
cardiotoxicity
present
an
update
on
cardioprotective
strategies
this
disorder.
Specifically,
focus
that
can
protect
cover
different
therapeutic
modalities
encompassing
small
molecules,
post-transcriptional
regulators,
transfer.
We
also
discuss
shortcomings
existing
models
explore
advances
in
human
pluripotent
stem
cell
derived
cardiomyocytes
a
platform
facilitate
identification
novel
treatments
against
Circulation Research,
Journal Year:
2020,
Volume and Issue:
128(1)
Published: Oct. 23, 2020
Previous
translational
studies
implicate
plasma
extracellular
microRNA-30d
(miR-30d)
as
a
biomarker
in
left
ventricular
remodeling
and
clinical
outcome
heart
failure
(HF)
patients,
although
precise
mechanisms
remain
obscure.
Cells,
Journal Year:
2019,
Volume and Issue:
8(11), P. 1433 - 1433
Published: Nov. 13, 2019
T
cells
play
a
critical
role
in
the
pathogenesis
of
systemic
lupus
erythematosus
(SLE),
which
is
severe
autoimmune
disease.
In
past
60
years,
only
one
new
therapeutic
agent
with
limited
efficacy
has
been
approved
for
SLE
treatment;
therefore,
development
early
diagnostic
biomarkers
and
targets
desirable.
Mitogen-activated
protein
kinase
kinases
(MAP4Ks)
dual-specificity
phosphatases
(DUSPs)
are
regulators
MAP
kinases.
Several
MAP4Ks
DUSPs
involved
T-cell
signaling
responses.
HPK1
(MAP4K1),
DUSP22
(JKAP),
DUSP14
negative
activation.
Consistently,
downregulated
human
patients.
contrast,
MAP4K3
(GLK)
positive
regulator
T-cell-mediated
immune
overexpression-induced
RORγt–AhR
complex
specifically
controls
interleukin
17A
(IL-17A)
production
cells,
leading
to
overexpressed
patients,
as
DUSP4
DUSP23.
addition,
also
either
diseases
(DUSP2,
DUSP7,
DUSP10,
DUSP12)
or
activation
(DUSP1,
DUSP5,
DUSP14).
this
review,
we
summarize
that
potential
and/or
SLE.
International Journal of Molecular Sciences,
Journal Year:
2020,
Volume and Issue:
21(12), P. 4354 - 4354
Published: June 19, 2020
Cardiovascular
diseases
(CVDs)
are
a
class
of
disorders
affecting
the
heart
or
blood
vessels.
Despite
progress
in
clinical
research
and
therapy,
CVDs
still
represent
leading
cause
mortality
morbidity
worldwide.
The
hallmarks
cardiac
include
dysfunction
cardiomyocyte
death,
inflammation,
fibrosis,
scar
tissue,
hyperplasia,
hypertrophy,
abnormal
ventricular
remodeling.
loss
cardiomyocytes
is
an
irreversible
process
that
leads
to
fibrosis
formation,
which,
turn,
induce
failure
with
progressive
dramatic
consequences.
Both
genetic
environmental
factors
pathologically
contribute
development
CVDs,
but
precise
causes
trigger
their
progression
largely
unknown.
lack
reliable
human
model
systems
for
such
has
hampered
unraveling
underlying
molecular
mechanisms
cellular
processes
involved
at
initial
stage
during
progression.
Over
past
decade,
significant
scientific
advances
field
stem
cell
biology
have
literally
revolutionized
study
disease
vitro.
Remarkably,
possibility
generate
disease-relevant
types
from
induced
pluripotent
cells
(iPSCs)
developed
into
unprecedented
powerful
opportunity
achieve
long-standing
ambition
investigate
level,
uncovering
mechanisms,
finally
translate
bench
discoveries
potential
new
therapeutic
strategies.
This
review
provides
update
on
previous
current
iPSC-driven
cardiovascular
modeling,
aim
underlining
stem-cell
biology-based
approaches
elucidation
pathophysiology
these
life-threatening
diseases.
International Journal of Molecular Sciences,
Journal Year:
2020,
Volume and Issue:
21(9), P. 3404 - 3404
Published: May 11, 2020
In
the
last
decade,
generation
of
cardiac
disease
models
based
on
human-induced
pluripotent
stem
cells
(hiPSCs)
has
become
common
use,
providing
new
opportunities
to
overcome
lack
appropriate
models.
Although
much
progress
been
made
toward
hiPSC-derived
cardiomyocytes
(hiPS-CMs),
several
lines
evidence
indicate
that
two-dimensional
(2D)
cell
culturing
presents
significant
limitations,
including
hiPS-CMs
immaturity
and
absence
interaction
between
different
types
extracellular
matrix.
More
recently,
advances
in
bioengineering
co-culture
systems
have
allowed
three-dimensional
(3D)
constructs
cells.
Within
these
systems,
biochemical
physical
stimuli
influence
maturation
hiPS-CMs,
which
can
show
structural
functional
properties
more
similar
those
present
adult
cardiomyocytes.
this
review,
we
describe
latest
2D-
3D-hiPSC
technology
for
mechanisms
investigation,
drug
development,
therapeutic
studies.